Introduction
Nitric oxide (NO) plays an important role in regulating blood vessel dilatation and the immune response, and functions as a neurotransmission signal in the brain and peripheral nervous system. [1] [2] [3] NO is synthesized from arginine by nitric oxide synthase (NOS) in vivo. At present, the genes for three isoforms of NOS have been cloned: brain NOS (bNOS or type I), endothelial NOS (eNOS or type III), and inducible NOS (iNOS or type II). bNOS and eNOS are expressed constitutively in the neurosystem and endothelium, respectively. iNOS expression is induced by immune stimulations such as lipopolysaccharide (LPS), interferon ␥ (INF ␥), or tumor necrosis factor ␣ (TNF ␣), in rodent macrophages. Recent studies have shown that NO may be involved in cell proliferation, differentiation, 4 and apoptosis. [5] [6] [7] Some tumors are reported to express the iNOS gene and NO is thought to affect the clinicopathological features of the tumors expressing iNOS. 8, 9 Regarding human lymphocytes, constitutive, low-level iNOS expression was detected in Epstein-Barr virus (EBV)-infected B cells, and NO inhibited apoptosis and EBV reactivation in these cells. 5 In splenic B cells, NO was also reported to play a role in regulating bcl-2 expression and cell survival. 6 Adult T cell leukemia/lymphoma (ATL) is a human T lym- ATL is classified into four clinical subtypes: smoldering, chronic, acute and lymphoma types. The latter two types are highly aggressive and have a poor prognosis. Clinically, ATL cells often infiltrate to organs such as skin, lung, and liver. For proliferation in such organs, sufficient blood supply to infiltrated ATL cells may be required. NO has been reported to play a role in vascularization or permeability of the vascular wall;
11-15 thus, we thought that NO might be associated with the invasive character of ATL cells.
In this study, we analyzed iNOS expression by reverse transcriptase-polymerase chain reaction (RT-PCR) in ATL patients and HTLV-I-infected cell lines, and compared the results with clinical features. We also showed that a NOS inhibitor caused cell proliferation retardation and apoptosis in an ATL-derived cell line (K3T).
Materials and methods

Patients and cell lines
Primary ATL cells from nine patients, including three chronic, two acute and four lymphoma types, were obtained. All patients were admitted to Kumamoto University Hospital between 1985 and 1994. The lymphocytes and ATL cells in peripheral blood were counted after May-Giemsa staining. The subjected cells from patients were harvested after centrifugation on a Ficoll-Hypaque gradient. After centrifugation, the cells were washed with PBS and provided for the flowcytometric analyses and the cell pellets were stocked in nitrogen liquid for further analyses. Postmortem studies were performed in cases 4, 6 and 8. Histological examinations were performed on skin biopsy specimens of case 1 and on autopsy specimens. Case 1 presented systemic eruption, and the skin biopsy confirmed infiltration of ATL cells. Histological examinations of cases 4 and 6 showed infiltration of ATL cells into lung, spleen, kidney, liver and intestine. In case 8, swelling of numerous intra-abdominal lymph nodes was observed, but invasion of ATL cells into other organs was not seen. SKT1B, 16 ED, 17 HUT102 18 and K3T 19 cell lines were derived from ATL patients. MT2, 20 YT-1 21 and YY cell lines were established by in vitro HTLV-I infection to umbilical cord blood cells, T cells from a paroxysmal nocturnal hemoglobinuria patient, and T cells from a normal healthy donor, respectively. CEM is an HTLV-I-negative T cell line. A172 is a human glioblastoma cell line 22 which expresses iNOS when induced by LPS, TNF ␣, or IFN ␥ treatment. The total RNA from LPS-, TNF␣-, IFN ␥-treated A172 cells was provided by Dr T Akaike of the Department of Microbiology, Kumamoto University School of Medicine, and used as a positive control for iNOS expression.
Immunophenotypic analysis
Cell surface marker analysis was performed as described previously. 23 
RT-PCR
The total RNAs were isolated from the frozen cell pellets of patients and packed cells of the cell lines by acid-guanidine phenol-chloroform extraction. First-strand DNA was made from 1 g of total RNA using Superscript II reverse transcriptase (GIBCO BRL, Gaithersburg, MD, USA) and random hexamers (25 pmol) as primers (Perkin-Elmer Cetus, Foster City, CA, USA), following the manufacturer's instructions. Out of a total of 20 l, 3l of the resulting cDNA was PCR amplified in 25-l reactions using Pfu DNA polymerase (Stratagene, San Diego, CA, USA) and primers specific for human hepatic iNOS. 25 The reaction mixture included 2 U of Pfu polymerase and 50 pmol of each primer. The primer pairs were designed by referring to a previous report: 5 (5Ј-CTGTCCTTGG-AAATTTCTGTT-3Ј and 5Ј-TGGCCAGATGTTCCTCTATT-3Ј, nucleotide sequences 212-232 and 699-680 of hepatic iNOS cDNA, respectively). The PCR conditions were: denaturation once at 95°C for 5 min, and then 35 cycles of 1 min of denaturation at 95°C, 1 min of annealing of 58°C, and 2 min of extension at 72°C, using a Robo-Cycler system (Stratagene). Ten microliters of each PCR product was separated in a 1.2% agarose gel and visualized by 0.5 g/ml ethidium bromide staining.
Sequence analysis
The PCR product from A172 cDNA was ligated into the Hincll site of plasmid pcDNAII (Stratagene) and then cloned. The sequence was determined by an auto sequencer system.
Southern blot analysis
The PCR products were transferred on to nylon membranes (Hybond+, Amersham, Japan). The blots were prehybridized at 65°C for 2 h, and hybridized overnight to a 32 P-labeled iNOS cDNA-specific fragment (398 bp) at 65°C. To avoid cross-hybridization to the primers, we generated a 398-bp fragment by PCR using internal iNOS primers (5Ј-AGTATGCAATGAATGGGGAA-3Ј and 5Ј-ATTCGATAGCTT-GAGGTAGA-3Ј, nucleotide sequences 250-269 and 642-623 of hepatic iNOS cDNA, respectively) (Ref. 25 and GenBank database, accession No. L09210) and A172 cDNA as template. The hybridized blots were washed twice in 2 × SSC/0.1% SDS at room temperature for 10 min, and twice in 0.1 × SSC/0.1% SDS at 65°C for 1 h. The blots were exposed to X-ray film at −80°C.
Cell culture and assays for cell growth and apoptosis
K3T and CEM were cultured in RPMI 1640 medium containing 10% fetal calf serum in the presence or absence of a NOS inhibitor (NG-monomethyl-l-arginine; L-NMMA purchased from Sigma Chemical, St Louis, MO, USA). The RPMI 1640 medium contained 1.15 mm of l-arginine. Before determination of the initial cell density, we examined the survival curve of both cell lines for 72 h. To avoid cell death due to over-growth during the experiments, we started the cell culture at initial cell density 12 × 10 5 /ml. The dose of L-NMMA utilized in this study was determined according to a previous report. 5 The viable cell numbers were estimated by conventional trypan-blue exclusion. DNA contents were determined as described elsewhere. 24 Briefly, the cells were fixed in 70% ethanol on ice for 1 h, then stained with 50 g/ml propidium iodine. The cells were washed twice with 1 × PBS and analyzed by flow cytometry (FACScan; Becton Dickinson). The fragmented DNA was extracted as previously described, 26 and electrophoresed in 1.5% agarose gels containing 0.5 g/ml ethidium bromide.
Results
Detection of iNOS mRNA by RT-PCR in HTLV-Iinfected cells and ATL cells
Using RT-PCR, the expected 491-bp RT-PCR product was detected in ethidium bromide-stained gels (Figure 1a) . The 491-bp fragment derived from A172 cDNA was shown to be identical to human hepatic iNOS cDNA by sequence analysis (data not shown). To confirm these products as the iNOS cDNA fragment, we performed Southern blot analysis using the 398-bp fragment of iNOS cDNA as a probe. As shown in Figure 1b , the expected hybridized signal was detected in the RT-PCR products, indicating that these bands were iNOS cDNA fragments. No RT-PCR product was obtained from normal peripheral blood mononuclear cell samples using iNOSspecific primers. Three ATL-derived cell lines (SKT1B, ED and K3T) and three in vitro transformed cell lines (MT2, YY and YT-1) were positive for iNOS expression. On the other hand, the HTLV-I-negative T cell line CEM was negative for iNOS. We could detect the iNOS mRNA by Northern analysis only in the RNA sample from A172 (data not shown).
Clinical features and iNOS in ATL patients
Among nine primary ATL samples, four were positive for expression of iNOS gene ( Figure 1 and Table 1 ). The iNOSpositive patients included two of three chronic, one of two acute, and one of four lymphoma types. Four of nine patients had involvement of organs and three out of four patients expressed iNOS gene (Table 1) .
Cell growth retardation and apoptosis caused by a NOS inhibitor (L-NMMA)
In iNOS-positive EBV-infected B cells, the NOS inhibitor N Gmonomethyl-l-arginine (L-NMMA) caused apoptosis. 5 Thus, we examined the effect of L-NMMA on cell growth of ATL cells. The K3T cell line showed the strongest expression of iNOS when analyzed by RT-PCR; therefore, we compared K3T and an iNOS-negative T cell line, CEM. As shown in Figure 2 , L-NMMA inhibited cell growth in a dose-dependent manner. Time course experiments showed that 5 mm L-NMMA caused growth retardation of K3T cell (Figure 3 ). To further examine the effect of L-NMMA on cell growth, we analyzed the cellular DNA content by flow cytometry. Figure 4a shows the dosage effect of L-NMMA on DNA content. In K3T cells, the proportion of cells with normal chromosome DNA content (2 n or 4 n) was decreased, while the proportion of cells having hypodiploid DNA content (below 2 n) was increased. DNA ladder formation was observed in L-NMMAtreated K3T cells, indicating that apoptosis had occurred ( Figure 4b ). As seen in Figure 5 , increasingly longer treatment with 5 mm L-NMMA caused an increasingly greater number of cells with lower DNA content. No such effect was observed in CEM cells (Figures 4 and 5) . We examined the effect of L-NMMA on cell growth of ED cell line. ED cell showed cell growth inhibition by addition of L-NMMA, but we could not confirm the evidence of apoptosis in the cell line.
Discussion
Various human tumor cells have been reported to express iNOS, and NO appears to affect clinical features and pathological aspects of the tumors. A previous study revealed that Burkitt's lymphoma and EBV-infected B cells show low-level, constitutive expression of iNOS. 5 ATL is also a virus-associated lymphoid malignancy; thus, we asked whether iNOS was expressed in ATL cells. Three out of four ATL-derived cell lines and three out of three in vitro HTLV-l-infected cell lines expressed iNOS. In normal PBMC, iNOS was not detected. These results suggested that HTLV-l infection caused iNOS expression in T lymphocytes. We also found iNOS expression in freshly isolated cells from four patients. ATL cells are known to produce various kinds of cytokine; therefore, we
Figure 2
Growth inhibition of iNOS positive-ATL cell line (K3T) caused by a NOS inhibitor (L-NMMA). K3T and CEM cells growing in early log phase were cultured in various concentrations of L-NMMA for 48 h. The viable cells were counted using trypan-blue exclusion. To avoid cell death of over-growth during the experiments, we started the cell culture at initial cell density 1.2 × 10 5 /ml. After 48 h culture, the cell count of the two cell lines was different due to its own cell growth rate.
Figure 3
Retardation of K3T cell growth by L-NMMA. The cells were cultured in 5 mm L-NMMA-containing medium. The viable cells were counted using trypan-blue exclusion.
could not rule out the possible iNOS expression from other activated cells such as monocytes than from ATL cells in patient's samples. Molecular mechanism of the iNOS expression in ATL is not known, but previous studies showed that the viral Tax protein activates the transcriptional regulatory potential of nuclear factor-kappa B (NF-B) in ATL cells. 27, 28 NF-B binding DNA elements exist in the 5Ј region of the iNOS gene, which is responsible for regulation of iNOS gene expression. 29, 30 Moreover, HTLV-I-Tax protein elevate iNOS expression in human monocytoid cell line (U937). 31 Thus, the viral Tax protein or activation of NF-B may play a partial role in constitutive iNOS expression in ATL cells. Recently, iNOS expression was also demonstrated in a hairy cell leukemia cell line 32 and B chronic lymphocytic leukemia cells. 33 Our results showed that HTLV-I-infected T cells also expressed iNOS mRNA.
ATL patients show various prognoses and clinical features. In central nervous system tumors, pathological grade has been shown to be correlated with NOS activity, and iNOS was expressed in highly anaplastic astrocytoma or glioblastoma. 9 ATL is classified into four subtypes on the basis of clinical features. Our results suggested that iNOS expression and clinical subtype seemed not to be correlated. Next, we examined the relationship between iNOS expression and organ involvement. Three of four iNOS-positive patients had infiltration of ATL cells into skin, lung or liver, whereas only one of five iNOS-negative patients showed hepatomegaly and an elevated serum transaminase value. On the basis of these results, we speculated that iNOS-positive ATL cells might have a tendency to invasively proliferate in organs. Only a limited number of patients was analyzed; thus, further studies are required for understanding iNOS expression and clinicopathological aspects of ATL.
A previous study revealed that NOS inhibitors induced apoptosis in EBV-infected B cells. 5 Thus, we examined the effect of a NOS inhibitor on cell growth of an iNOS-positive Time course of effects of L-NMMA on growth of K3T cells. The cells were cultured in 5 mm L-NMMA-containing medium. In L-NMMA-containing medium, the number of cells with hypodiploid DNA content (arrow) was increased.
ATL cell line, K3T. In K3T cells, growth inhibition and apoptosis were induced by a NOS inhibitor, L-NMMA. These results were similar to those in EBV-positive B cells. NO plays a role in the control of apoptosis as both inducer and suppressor. 34, 35 At present, many physiological effects of NO have been reported, and NO has been implicated in redox regulation in cells. 36 Regarding ATL, the ATL-derived factor (ADF), which augments interleukin 2 receptor expression on ATL cells, has been shown to be a redox regulator. 37 The NO produced by iNOS in ATL cells may be involved in cellular redox regulation and may play a role in cell survival. 
